The first cancer patients are to receive doses of an innovative new drug that targets a master regulatory pathway in cells, as part of a new clinical trial.

Adding abiraterone to the standard treatment for locally advanced prostate cancer, where the cancer has a high chance of spreading*, could halve the risk of death from the disease.

The number of cancer patients entering clinical trials has plummeted during the pandemic – denying many thousands the latest treatment options and delaying the development of cutting-edge drugs and technologies.